Skip to Content
Merck
CN

HCKP1-11K-PX17

MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel

Premixed Human Immuno-Oncology Checkpoint Protein 17-Plex Panel 1

Synonym(s):

17-Plex Immuno-Oncology Kit, Human Checkpoint Protein Panel, Immuno-Oncology 17-Plex Panel

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.77
UNSPSC Code:
12161503
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel,

description

Premixed Human Immuno-Oncology Checkpoint Protein 17-Plex Panel 1

species reactivity

human

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

technique(s)

multiplexing: suitable

input

plasma
cell culture supernatant(s)

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

General description

Immune checkpoint proteins are regulators of immune activation and play a key role in maintaining immune homeostasis, preventing autoimmunity, and are involved in cancer immune escape. These immune system molecules demonstrate the ability to act both as agonists (co-stimulatory checkpoint molecules) or antagonists (co-inhibitory checkpoint molecules) of immune response. Immune checkpoint inhibitor drugs targeting inhibitory immune checkpoint proteins, such as CTLA-4 and PD-L1, have demonstrated efficacy in cancer immunotherapy by improving the antitumor immune response and saving lives in the treatment of many malignancies. Immune checkpoint proteins may express on immune cells and/or tumor cells as activating receptors or inhibitory receptors. Many immune checkpoint proteins are also expressed as soluble forms in circulation and in the tumor and tumor microenvironment and are putative biomarkers for immunotherapy in various diseases including cancer.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze 17 analytes in human serum, plasma, and cell culture supernatants.

Analytes included: BTLA (B- and T-lymphocyte attenuator), CD27 (Cluster of differentiation 27), CD28 (Cluster of differentiation 28), CD40 (Cluster of differentiation 40), CD80/B7-1 (Cluster of differentiation 80/B7-1), CD86/B7-2 (Cluster of differentiation 86/B7-2), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), GITRL (Ligand for receptor TNFRSF18/AITR/GITR), GITR (Glucocorticoid-induced TNFR-related protein), HVEM (Herpesvirus entry mediator), ICOS (Inducible T-cell costimulator), LAG-3 (Lymphocyte-activation gene 3), PD-L1 (Programmed death-ligand 1), PD-L2 (Programmed death-ligand 2), PD-1 (Programmed cell death protein 1), TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), TLR-2 (Toll like receptor 2)

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

  • Simultaneous Immune Checkpoint Analysis: Quantify 17 co-stimulatory (CD28, ICOS) and co-inhibitory (PD-1, CTLA-4) proteins in a single assay using a multiplex immuno-oncology panel, enabling efficient study of immune activation pathways and cancer immunotherapy mechanisms.
  • Premixed Bead Convenience: Ready-to-use magnetic beads eliminate manual preparation, reducing setup time and ensuring consistent batch-to-batch performance.
  • Therapeutic Relevance: Directly aligns with immune checkpoint inhibitor research (e.g., anti-PD-1/PD-L1 therapies) to advance oncology outcomes.
  • Standardized Protocols: Pre-optimized dilution guidelines (1:2 for serum/plasma) minimize experimental variability.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.


Still not finding the right product?


signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

Storage Class

10 - Combustible liquids

wgk

WGK 3

Regulatory Information

新产品

This item has



Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library


Related Content

The newer xMAP® Sheath Fluid PLUS formulation contains 3 modes of microbial action to eliminate potential environmental microbial resistance. See how the preparations compare in this performance comparison of the previous xMAP® Sheath Fluid to the new xMAP® Sheath Fluid PLUS formulation in MILLIPLEX® multiplex assays.